New arrhythmia drug provides only modest efficacy and no clear safety benefits say researchers
In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.
Apr 05, 2010
not rated yet
0
